Eli Lilly and Company (NYSE:LLY – Get Free Report) announced its earnings results on Wednesday. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98, FiscalAI reports. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 103.84%. The firm’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.31 EPS. Eli Lilly and Company updated its FY 2026 guidance to 35.500-36.500 EPS.
Here are the key takeaways from Eli Lilly and Company’s conference call:
- Q2 revenue rose 48% year over year to $6.8 billion of incremental growth from key products, led by Mounjaro and Zepbound; non-GAAP EPS increased to $8.38 from $6.31.
- Lilly raised its 2026 outlook, increasing the revenue range to $85 billion-$87 billion and non-GAAP EPS guidance to $35.50-$36.50, reflecting stronger-than-expected first-half performance.
- Foundayo’s launch is gaining traction as access expands through major PBMs and the Medicare GLP-1 Bridge program; Lilly reported recent prescription acceleration, 36,000 U.S. prescribers, and encouraging initial international demand.
- The pipeline produced several important advances, including positive phase III retatrutide results, an FDA submission for orforglipron in diabetes, strong oncology data for pirtobrutinib and selpercatinib, and regulatory progress for weekly insulin efsitora alfa.
- U.S. net pricing declined, with reported price down 3% and an underlying decline of approximately 9% excluding rebate and discount adjustments; management also cautioned that prior-period adjustments and seasonal factors will affect second-half comparisons.
Eli Lilly and Company Trading Down 0.4%
Shares of NYSE LLY traded down $5.23 on Friday, reaching $1,186.71. 1,665,277 shares of the company traded hands, compared to its average volume of 3,134,788. The stock has a market capitalization of $1.12 trillion, a PE ratio of 39.82, a P/E/G ratio of 1.41 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The company has a 50 day moving average of $1,157.76 and a 200 day moving average of $1,046.57.
Eli Lilly and Company Dividend Announcement
Institutional Investors Weigh In On Eli Lilly and Company
Institutional investors have recently bought and sold shares of the stock. Mcguire Capital Advisors Inc. acquired a new stake in Eli Lilly and Company during the fourth quarter worth about $38,000. TMB Capital Partners LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $456,000. Strive Financial Group LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $1,950,000. Widmann Financial Services Inc. increased its position in Eli Lilly and Company by 7.8% during the 4th quarter. Widmann Financial Services Inc. now owns 1,038 shares of the company’s stock worth $1,116,000 after purchasing an additional 75 shares in the last quarter. Finally, First Commonwealth Financial Corp PA increased its position in Eli Lilly and Company by 3.1% during the 4th quarter. First Commonwealth Financial Corp PA now owns 2,078 shares of the company’s stock worth $2,233,000 after purchasing an additional 62 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on the stock. Guggenheim raised their price target on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, July 1st. Jefferies Financial Group upped their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research note on Tuesday, June 9th. Sanford C. Bernstein lifted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 14th. Finally, Wells Fargo & Company boosted their price target on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,292.18.
Read Our Latest Research Report on Eli Lilly and Company
Trending Headlines about Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Strong Q2 beat and raised outlook: Lilly reported adjusted earnings of $8.38 per share versus the $6.40 consensus, while revenue rose 47.7% year over year to $22.97 billion. Management raised 2026 revenue guidance to $85 billion-$87 billion from $82 billion-$85 billion, largely because of surging demand for Mounjaro and Zepbound. Eli Lilly raises 2026 outlook again as Q2 soars past estimates
- Positive Sentiment: Weight-loss portfolio remains the growth engine: Mounjaro sales increased 91%, and Mounjaro and Zepbound together generated nearly $15 billion in quarterly sales—almost two-thirds of total revenue. The results strengthened investor confidence that Lilly is widening its lead over Novo Nordisk in the obesity-drug market. Eli Lilly Stock Jumps Over 5% as Mounjaro Sales Surge 91%
- Positive Sentiment: Analyst support increased: Truist raised its price target to $1,376 and maintained a Buy rating, while Cantor Fitzgerald lifted its target to $1,410 with an Overweight rating. Analysts cited strong incretin performance and a favorable long-term growth outlook. Eli Lilly’s Incretin Performance Supports Long-Term Growth, Truist Says
- Positive Sentiment: Pipeline and access catalysts: Foundayo adoption is accelerating, Medicare obesity-drug access is expanding, and retatrutide is advancing toward a potential 2027 regulatory filing. Lilly is also offering retatrutide to certain patients through an early-access program before FDA approval, potentially building familiarity with its next-generation obesity treatment. Eli Lilly offers new weight loss drug to some patients before FDA approval
- Neutral Sentiment: A court victory for Lilly and Novo Nordisk in an antitrust lawsuit removes a legal overhang, although it does not materially change near-term earnings expectations. Lilly, Novo defeat antitrust lawsuit over GLP-1 drug market
- Negative Sentiment: After the earnings-driven advance, Lilly’s premium valuation leaves less room for execution mistakes. Investors are monitoring manufacturing capacity, competition, and whether rapidly rising GLP-1 demand can be sustained. Amazon’s $50-per-month Medicare access program for competing obesity drugs could also increase pressure on pricing and distribution. Amazon Is Bringing the Weight-Loss Drug Race to Medicare
Eli Lilly and Company Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
